Selepressin

Selepressin

Systematic (IUPAC) name
1-({(4R,7S,10S,13S,16S,19R)-19-Amino-10-(4-amino-4-oxobutyl)-7-(2-amino-2-oxoethyl)-16-benzyl-13-[(2S)-2-butanyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-N^5-isopropyl-L-ornithylglycinamide
Identifiers
CAS Number	876296-47-8
ATC code	None
PubChem	CID 53330936
ChemSpider	26609297
Chemical data
Formula	C46H73N13O11S2
Molar mass	1048.282 g/mol
SMILES CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)Cc2ccccc2)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCCC(=O)N
InChI InChI=1S/C46H73N13O11S2/c1-5-26(4)38-45(69)54-30(14-9-17-35(48)60)41(65)56-32(21-36(49)61)42(66)57-33(24-72-71-23-28(47)39(63)55-31(43(67)58-38)20-27-12-7-6-8-13-27)46(70)59-19-11-16-34(59)44(68)53-29(15-10-18-51-25(2)3)40(64)52-22-37(50)62/h6-8,12-13,25-26,28-34,38,51H,5,9-11,14-24,47H2,1-4H3,(H2,48,60)(H2,49,61)(H2,50,62)(H,52,64)(H,53,68)(H,54,69)(H,55,63)(H,56,65)(H,57,66)(H,58,67)/t26-,28-,29-,30-,31-,32-,33-,34-,38-/m0/s1 Key:JCVQBJTWWDYUFQ-MRUTUVJXSA-N

Selepressin (INN) (code name FE-202158), also known as [Phe(2),Ile(3), Hgn(4),Orn(iPr)(8)]vasopressin) is a potent, highly selective, short-acting peptide full agonist of the vasopressin 1A receptor and analog of vasopressin which is under development by Ferring Pharmaceuticals for the treatment of vasodilatory hypotension in septic shock.^[1][2][3][4]

References

1. Jeremy I Levin (24 October 2014). Macrocycles in Drug Discovery. Royal Society of Chemistry. pp. 313–. ISBN 978-1-84973-701-2.
2. Jean-Louis Vincent (23 September 2012). Annual Update in Intensive Care and Emergency Medicine 2012. Springer Science & Business Media. pp. 80–. ISBN 978-3-642-25716-2.
3. J. L. Vincent (2 September 2008). Yearbook of Intensive Care and Emergency Medicine 2008. Springer Science & Business Media. pp. 427–. ISBN 978-3-540-77290-3.
4. Laporte, R.; Kohan, A.; Heitzmann, J.; Wisniewska, H.; Toy, J.; La, E.; Tariga, H.; Alagarsamy, S.; Ly, B.; Dykert, J.; Qi, S.; Wisniewski, K.; Galyean, R.; Croston, G.; Schteingart, C. D.; Riviere, P. J.- M. (2011). "Pharmacological Characterization of FE 202158, a Novel, Potent, Selective, and Short-Acting Peptidic Vasopressin V1a Receptor Full Agonist for the Treatment of Vasodilatory Hypotension". Journal of Pharmacology and Experimental Therapeutics 337 (3): 786–796. doi:10.1124/jpet.111.178848. ISSN 0022-3565.